Related Experiment Video

Updated: Sep 12, 2026

Isolation of Cerebral Capillaries from Fresh Human Brain Tissue
06:35

Isolation of Cerebral Capillaries from Fresh Human Brain Tissue

Published on: September 12, 2018

Individual blood-brain barrier phenylalanine transport in siblings with classical phenylketonuria

J Weglage1, D Wiedermann, J Denecke

  • 1Department of Pediatrics, University of Münster, Münster, Germany. weglage@uni-muenster.de

Journal of Inherited Metabolic Disease
|January 31, 2003
PubMed

Insights

Individual differences in phenylalanine transport across the blood-brain barrier significantly impact phenylketonuria (PKU) patient outcomes, affecting IQ and brain health despite dietary control.

Area of Science:

  • Biochemistry
  • Neuroscience
  • Genetics

Background:

  • Phenylketonuria (PKU) is a genetic disorder requiring strict dietary management.
  • Individual clinical outcomes in PKU patients vary despite comparable dietary control.
  • Blood-brain barrier (BBB) transport of phenylalanine is a potential factor influencing these variations.

Purpose of the Study:

  • To investigate the role of individual phenylalanine BBB transport characteristics in PKU.
  • To correlate brain phenylalanine levels with clinical outcomes in PKU siblings.
  • To determine if BBB transport explains differing patient prognoses.

Main Methods:

  • Studied four pairs of siblings with classical PKU and identical genotypes.
  • Utilized in vivo nuclear magnetic resonance spectroscopy during an oral phenylalanine load.
  • Measured blood and brain phenylalanine concentrations, transport kinetics (Kt,app), and transport capacity (Tmax/Vmet).

Main Results:

  • Significant interindividual differences in brain phenylalanine levels were observed, even with similar blood levels.
  • Apparent transport Michaelis constant (Kt,app) varied from 0.10 to 0.84 mmol/L.
  • Lower Kt,app, higher Tmax/Vmet ratios, and elevated brain phenylalanine correlated with lower IQ and increased white matter abnormalities.

Conclusions:

  • Individual blood-brain barrier transport characteristics are critical determinants of clinical outcomes in PKU.
  • Resultant brain phenylalanine levels, not just blood levels, causally influence neurological deficits.
  • Understanding BBB transport is essential for personalized PKU management and predicting patient prognosis.

More Related Videos

A Simple and Reproducible Method to Prepare Membrane Samples from Freshly Isolated Rat Brain Microvessels07:13

A Simple and Reproducible Method to Prepare Membrane Samples from Freshly Isolated Rat Brain Microvessels

Published on: May 7, 2018

Visualizing the Gatekeeper: Evan's Blue Dye-Based Assessment of Blood-Brain Barrier Permeability in Adult Zebrafish06:49

Visualizing the Gatekeeper: Evan's Blue Dye-Based Assessment of Blood-Brain Barrier Permeability in Adult Zebrafish

Published on: September 30, 2025

Related Concept Videos

Pedigree Analysis02:21

Pedigree Analysis

A pedigree is a diagram displaying a family’s history of a trait. Analyzing pedigrees can reveal (1) whether a trait is dominant or recessive, (2) the type of chromosome, autosomal or sex, a trait is linked to, (3) genotypes of family members, and (4) probabilities of phenotypes in future generations. For families with a history of autosomal or sex-linked diseases, this information can be crucial to family planning.Pedigrees Display Family HistoriesIn various plant and animal species,...
Physiological Barriers01:25

Physiological Barriers

Physiological barriers are semi-permeable cellular structures restricting drug diffusion into intracellular compartments and tissues. There are six types of physiological barriers: blood endothelial, cell membrane, blood-brain, blood-cerebrospinal fluid (CSF), blood-placenta, and blood-testis barriers.
The blood endothelial barrier is the most porous of these. It allows all small ionized, un-ionized, and lipophilic molecules to pass through the endothelial lining into the interstitial space...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...